SciSparc
SciSparc
SPRC
NASDAQ
0.36
USD
-55.56%
About
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 3.7M |
| Three Month Average Volume | 69.5M |
| High Low | |
| Fifty-Two Week High | 14.2199 USD |
| Fifty-Two Week Low | 0.301 USD |
| Fifty-Two Week High Date | 24 Nov 2023 |
| Fifty-Two Week Low Date | 16 Aug 2024 |
| Price and Volume | |
| Current Price | 0.3601 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -7.88% |
| Thirteen Week Relative Price Change | -63.82% |
| Twenty-Six Week Relative Price Change | -91.75% |
| Fifty-Two Week Relative Price Change | -93.09% |
| Year-to-Date Relative Price Change | -93.77% |
| Price Change | |
| One Day Price Change | -2.39% |
| Thirteen Week Price Change | -61.28% |
| Twenty-Six Week Price Change | -90.93% |
| Five Day Price Change | -1.88% |
| Fifty-Two Week Price Change | -91.34% |
| Year-to-Date Price Change | -92.62% |
| Month-to-Date Price Change | -18.53% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 10.77433 USD |
| Book Value Per Share (Most Recent Quarter) | 0.03439 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 6.26167 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.03439 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.23668 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 8.11077 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -14.43 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.21742 USD |
| Normalized (Last Fiscal Year) | -14.43 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -14.43 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.21742 USD |
| Including Extraordinary Items (Last Fiscal Year) | -14.43 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.50969 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 7.18288 USD |
| Cash Per Share (Most Recent Quarter) | 0.27602 USD |
| Cash Flow Per Share (Last Fiscal Year) | -15.05803 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.11343 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.24627 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -776 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -203.58% |
| Pretax Margin (5 Year) | -526.31% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 76.28% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -236.71% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -668.98% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -204.34% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -527.17% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 215.65% |
| Tangible Book Value (5 Year) | 88.69% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -41.89% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -33.86% |
| EPS Change (Trailing Twelve Months) | 44.57% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 20 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -338,000 |
| Net Debt (Last Fiscal Year) | -5,000,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 10 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 4 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -5,887,000 |
| Free Cash Flow (Trailing Twelve Months) | -7,149,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 1 |
| Total Debt to Equity (Most Recent Quarter) | 620 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -54.00% |
| Return on Assets (Trailing Twelve Months) | -92.51% |
| Return on Assets (5 Year) | -69.39% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -72.84% |
| Return on Equity (Trailing Twelve Months) | -162.35% |
| Return on Equity (5 Year) | -107.68% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -83.52% |
| Return on Investment (Trailing Twelve Months) | -152.41% |
| Return on Investment (5 Year) | -111.07% |